

Draft Work Programme (WP) for the implementation of veterinary programmes in 2023-2024 (Single Market Regulation (EU) 2021/690)

Standing Committee on Plants, Animals, Food and Feed Section Animal Health and Welfare (meeting of 14 March 2022)

Unit G2
Animal Health
DG SANTE



Indicative timeline for adoption of the WP 2023-2024 (Single Market Programme Regulation (EU) 2021/690)

Adoption of Financing Decision and Work Programme 2023-2024 by:

- 30 April 2022 (date set in the SMP Regulation)
- Presentation at today PAFF (discussion), and at April PAFF before vote by written procedure
- Submission of veterinary programmes 2023: by 31 May 2022
- Signature of grant agreements: January 2023
- Implementation period : as from 1/1/2023



Draft Work Programme (WP) for the implementation of veterinary programmes in 2023-2024

Main points

- Objectives
- Criteria of prioritisation
- Priorities for EU co-funding in 2023-2024
- > Expected results
- Budget available, Co-funding rate to apply



Objectives

- To <u>prevent the introduction or re-introduction</u> of transboundary animal diseases in the EU
- To <u>enhance surveillance</u>, for early detection of disease outbreaks and cases for timely control or containment
- To control certain animal diseases and/or zoonosis, <u>reaching/maintaining</u> their prevalence below a certain level
- To <u>reduce prevalence / incidence</u> of certain endemic diseases, and achieve disease eradication where feasible



Criteria of prioritisation

- Prevention of epidemics or zoonoses
- Direct impact on human health
- Mandatory measures under EU legislation (based on Animal Health Law)
- Consolidation of the EU animal health situation
- Budget availability
- > Veterinary programme effectiveness in the past years



Priorities for EU co-funding in 2021-2022

• Group 1: diseases with major impact on animal health, human health, on trade and likely at risk to be introduced into the Union territory from third countries

African swine fever, avian influenza, Salmonella infections, rabies

• Group 2: diseases with limited impact on animal health and/or human health and close to eradication, where possible

TSE, bovine and sheep & goat brucellosis, classical swine fever, lumpy skin disease, peste des petits ruminants, sheep-goat pox

NB: Bovine tuberculosis: end of phasing out in 2023 (initiated in 2018)



Expected Results

- Early detection (e.g. Avian Influenza, African swine fever)
- ➤ No outbreaks (e.g. rabies, LSD, PPR, Sheep Goat Pox, CSF)
- Containment and reduction/stabilization of number of outbreaks (ASF)
- Increase the number of MSs with incidence below EU target (*zoonotic Salmonella*)
- Maintain number of cases below certain level, increase number of MSs with negligible risk (classical BSE),
- decrease the number of index cases of classical scrapie in sheep and goat in the EU;
- Decrease of prevalence/incidence, increase disease –free MS (TB, Bru)



Maximum budget available for vet programmes

2023 = 107 M EUR

2024 = 107 M EUR

Co-funding rate (CFR)

Group 1= 50%-75%

Group 2= 30%-45% (flexibility)

Bovine tuberculosis: 10/15% in 2023 (continuation of the phasing out initiated in 2018 for existing programmes)

100%: activities in TC* (mainly ASF/LSD/rabies)

NB: In case the budget requested by the MSs for their programmes exceeds 107 M€, the CFR for Group 2 will be proportionally decreased. On the other way round, Group 2 CFR may be increased

* no funding for programmes in Russia and Belarus (except for 2021 programmes where MS paid already)



Summary of the co-financing rates per group and per year

Co-financing rate Allocation	2021	2022	2023	2024
Group 1:	50/75/100	50/75/100	50/75/100	50/75/100
ASF – AI – rabies – Salmonella	EUR 62,421,000	EUR 72,898,000		
Group 2:	30/45	30/45	30/45	30/45
TSE – BV, OV and CP BRU –	35.3/53	28/42	i	ii
CSF – LSD – PPR – S&GP	EUR 27,556,000	EUR 21,623,000		
BV Tub	16/24	12/18	10/15	-
	EUR 16,976,000	EUR 12,441,000		
Total allocation	EUR 106,953,000 ⁱⁱⁱ	EUR 106,962,000iv	Maxi EUR 107,000,000°	Maxi EUR 107,000,000vi

¹ Actual CFR will be determined at later stage, once programmes (and intermediate reports) received

ii Actual CFR will be determined at later stage, once programmes (and intermediate reports) received

iii Final allocation

iv Initial allocation

v Planned maximum allocation

vi Planned maximum allocation



Please send your comments by 25 March 2022 to:

SANTE-CONSULT-G2@ec.europa.eu

Thank you for your attention